Travere Therapeutics (TVTX) Interest & Investment Income (2013 - 2026)
Travere Therapeutics posted quarterly Interest & Investment Income of $2.6 million for Q1 2026, down 31.91% year-on-year from $3.8 million in Q1 2025, and little changed on a QoQ basis from $2.6 million in Q4 2025.
Travere Therapeutics (TVTX) has 14 years of Interest & Investment Income data on file, last reported at $2.6 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 31.91% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (down 26.12% YoY), and the FY2025 full-year result was $12.7 million, down 28.6% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $2.6 million, roughly flat from $2.6 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $14.4 million in Q4 2022 and bottomed at -$2.8 million in Q3 2022.
- The 5-year median for Interest & Investment Income is $3.6 million (2023), against an average of $3.8 million.
- The widest annual swing landed in 2022, when Interest & Investment Income slumped 885.83%; it then soared 555.75% in 2023.
- A 5-year view of Interest & Investment Income shows it stood at $14.4 million in 2022, then tumbled by 50.44% to $7.2 million in 2023, then tumbled by 46.94% to $3.8 million in 2024, then sank by 31.7% to $2.6 million in 2025, then slipped by 0.31% to $2.6 million in 2026.
- The last three Interest & Investment Income figures came in at $2.6 million (Q1 2026), $2.6 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.58 Mn |
| Dec 31, 2025 | 2.59 Mn |
| Sep 30, 2025 | 3.05 Mn |
| Jun 30, 2025 | 3.29 Mn |
| Mar 31, 2025 | 3.80 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 4.42 Mn |
| Mar 31, 2024 | 6.03 Mn |
| Dec 31, 2023 | 7.15 Mn |
| Sep 30, 2023 | 5.84 Mn |
| Jun 30, 2023 | 5.13 Mn |
| Mar 31, 2023 | 3.65 Mn |
| Dec 31, 2022 | 14.43 Mn |
| Sep 30, 2022 | -2.83 Mn |
| Jun 30, 2022 | 782,000.00 |
| Mar 31, 2022 | -2.52 Mn |
| Dec 31, 2021 | -21.44 Mn |
| Sep 30, 2021 | 360,000.00 |
| Jun 30, 2021 | 988,000.00 |
| Mar 31, 2021 | 409,000.00 |
| Dec 31, 2020 | -4.76 Mn |
| Sep 30, 2020 | -4.77 Mn |
| Jun 30, 2020 | -4.63 Mn |
| Mar 31, 2020 | -4.89 Mn |
| Dec 31, 2019 | 24.29 Mn |
| Sep 30, 2019 | -4.55 Mn |
| Jun 30, 2019 | -4.82 Mn |
| Mar 31, 2019 | -4.87 Mn |
| Dec 31, 2018 | 10.35 Mn |
| Sep 30, 2018 | -2.53 Mn |
| Jun 30, 2018 | -1.06 Mn |
| Mar 31, 2018 | -1.16 Mn |
| Dec 31, 2017 | 6.55 Mn |
| Sep 30, 2017 | -660,000.00 |
| Jun 30, 2017 | -658,000.00 |
| Mar 31, 2017 | -132,000.00 |
| Dec 31, 2016 | -150,000.00 |
| Sep 30, 2016 | -299,000.00 |
| Jun 30, 2016 | -147,000.00 |
| Mar 31, 2016 | -163,000.00 |
| Dec 31, 2015 | -333,000.00 |
| Sep 30, 2015 | -695,000.00 |
| Jun 30, 2015 | -2.92 Mn |
| Mar 31, 2015 | -3.80 Mn |
| Dec 31, 2014 | -2.63 Mn |
| Sep 30, 2014 | -2.63 Mn |
| Jun 30, 2014 | -2.18 Mn |
| Mar 31, 2014 | 536.00 |
| Dec 31, 2013 | -46,009.00 |
| Sep 30, 2013 | 4.00 |
| Jun 30, 2013 | -5.00 |
| Mar 31, 2013 | 40,779.00 |